How the Lixte Biotechnology Holdings and dostarlimab study could influence future ovarian cancer trial design
Lixte Biotechnology’s LB-100 ovarian cancer data may signal a new immunotherapy pathway. Read what this could change for the sector.
Lixte Biotechnology’s LB-100 ovarian cancer data may signal a new immunotherapy pathway. Read what this could change for the sector.